| Prev Close | 162.38 |
| Open | 161.32 |
| Day Low/High | 160.06 / 162.48 |
| 52 Wk Low/High | 109.16 / 164.14 |
| Volume | 6.81M |
Johnson & Johnson (JNJ)
162.00
0.38
0.23
NYSE
| Exchange | NYSE |
| Shares Outstanding | 2632.54B |
| Market Cap | 428.53B |
| P/E Ratio | 28.61 |
| Div & Yield | N.A. (N.A) |
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Jim Cramer: The Real Lesson of the 10-Year Bull Market Anniversary
Did the Fed aid Microsoft? No, Microsoft aided Microsoft. J&J aided J&J. Procter aided Procter.
Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
The Charts of Johnson & Johnson Do Not Yet Convince Me of the Bull Case
Let's look at the charts and indicators to round out the picture.
Jim Cramer: This Market Has a Terrible Case of Attention Deficit Disorder
I think this truly defines what has gone on with tech stocks since the latest reporting period began.
How Are My Ideas Working Out? January Trade Review (Part 1)
Eight of these 11 trade ideas are in the green, with a few big winners.
Jim Cramer: This Strong Dollar Is Biting Deeply Into Apple
Dollar strength is affecting the competitive advantage of U.S. companies around the globe, and it is a more insidious problem that most people recognize.
The New Small Biotechs Heating Up the Medical Cannabis Space
These companies are working to plant their flag in a new landscape.
Jim Cramer: What Are We to Make of Today's Market Decline?
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
How to Play Johnson & Johnson Now That Earnings Are Out
There's a lot of runway left to adjust guidance numbers moving forward.
My Greatest Concern About Procter & Gamble Heading Into Earnings
Volatility appears to be the most attractive play during the early portion of earnings season.
Two Sticking Points With Johnson & Johnson: Guidance and Litigation Expense
While the ongoing litigation could be seen as a deterrent to investment, I think the more interesting story is its upcoming AFib detection study with Apple.
Johnson & Johnson: How the Stock Looks on the Charts After Earnings
Experienced traders could approach the long side carefully.
The Meat and Potatoes of This Global Economic Slowdown: Market Recon
It's centered around a few themed negatives, all forcing their own various uncertainties into free market price discovery.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon
Do we have to run for the hills? Not necessarily.
A Johnson & Johnson Volatility Trade
JNJ's current pennant pattern creates the potential for a big move in the month of January.
Johnson & Johnson Stock May Take a While to Rebound From Talc Hit
Shares have fallen hard, despite the company's vehement scientific and legal defense.
Johnson & Johnson Remains Dividend Stock Royalty
Despite recent talc powder risks, the long-term earnings power of this 'Dividend King' has not deteriorated.
Jim Cramer: This Is a Treacherous Bear Market
But even in bear markets you get spikes, usually short sharp ones.
It's Ugly Out There: Here's What I Suggest Traders Do Right Now
We are absolutely due for a rip-your-face-off rally in the wake of entering a bear market.
Now Is the Time to Play Defense
Remember, though, playing defense is very different than leaving the stadium altogether.
Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center
These are currently situations where companies are facing serious lawsuits.
Are Algos Jumping on J&J Headlines?
Are machines jumping on Johnson & Johnson's human risk headlines?
Chart of the Day: Johnson & Johnson's Punishment Appears Overdone
Putting J&J stock's selloff in a graphic illustrates the market's swift and violent reaction to the Reuters report.
Johnson & Johnson Challenges Reuters' Assertions About Its Product Safety
Shares continue to fall on Monday after Friday's swift descent.
Let's Get Real About Johnson & Johnson's Selloff and How to Play the Stock
I find a lot of Reuters' claims hard to believe. Even more difficult to believe is the selloff.
Johnson & Johnson Stock Presents a Buying Opportunity Amid an Overblown Selloff
Many analysts advise buying the shares on weakness because it's attractively priced.
